KDR and hereditary clear cell renal cell carcinoma: Drugs known as vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) can inhibit VEGFR, which have recently been approved and used in treating various cancers, such as renal cell carcinoma (RCC) and liver cancer (64, 65).